Pioneering and Affordable Strategies to Prevent Progression of Prediabetes, Obesity and CV Risk in Hispanics

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

The investigators are studying how to help people with prediabetes (Pre-DM) and obesity. The goal is to use new and affordable treatments to bring blood sugar levels back to normal and help participants to lose weight. The investigators also want to reduce participants risk of heart problems. The study team will look at how these treatments affect metabolism and other body functions to help find new ways to treat diabetes and obesity in the future.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients will have an established diagnosis of pre-Diabetes Mellitus (DM) before the screening visit, documented by an acceptable modality in the last 6 months.

• Age ≥ 18 years old

• Body Mass Index (BMI)=25-40 kg/m2

• Glycated Hemoglobin (HbA1c) = 5.7-6.4%

• Blood Pressure (BP) \<160/100

• Estimated Glomerular Filtration Rate (eGFR) ≥30 ml/min•1.73m2

• Body weight must be stable (±5 pounds) over the last 3 months.

• Oral diuretics, if prescribed to the patient according to local guidelines and discretion of the investigator, should be stable for at least 1 week prior to randomization.

• Hispanic ethic group

⁃ Willing to adhere to medication regimen for up to 6 months.

⁃ Male or female, if female, met these criteria:

∙ Not pregnant or breast-feeding

‣ Negative pregnancy test result at visit 1 (screening)

‣ During the entire study, women of childbearing potential (WOCBP) including peri-menopausal women who have a menstrual period within 1 year must practice appropriate, and effective birth control, either implants or pills, or a vasectomized partner prior to receiving the first dose of study medication

⁃ Does not suffer from severe claustrophobia

⁃ No contraindication for Magnetic Resonance Imaging (MRI) (metal plates, screws, shrapnel, pins, or cardiac pacemaker)

Locations
United States
Texas
University of Texas Health Science Center at San Antonio
RECRUITING
San Antonio
Contact Information
Primary
Carolina Solis-Herrera, MD
solisherrera@uthscsa.edu
210-567-4900
Backup
Francisca Acosta, PhD
acostafm@uthscsa.edu
Time Frame
Start Date: 2024-09-11
Estimated Completion Date: 2027-07
Participants
Target number of participants: 64
Treatments
Placebo_comparator: Placebo
Randomization will occur 1:1:1:1 to this placebo group
Experimental: SGLT2 inhibitor Group
Randomization will occur 1:1:1:1 to this SGLT2 inhibitor group
Experimental: GLP-1 Receptor Agonist Group
Randomization will occur 1:1:1:1 to this GLP-1 receptor agonist group
Experimental: Metformin with SGLT2 Inhibitor Group
Randomization will occur 1:1:1:1 to this metformin plus SGLT2 inhibitor group
Related Therapeutic Areas
Sponsors
Leads: The University of Texas Health Science Center at San Antonio
Collaborators: Baptist Health Foundation of San Antonio

This content was sourced from clinicaltrials.gov